Patient Death Won’t Slow Research on “Off-the-Shelf” Immune Cells to Treat Cancer – MIT Technology Review
MIT Technology Review |
Patient Death Won't Slow Research on “Off-the-Shelf” Immune Cells to Treat Cancer
MIT Technology Review The highly personalized treatment, called CAR–T therapy, uses a patient's own immune cells and takes about three weeks to manufacture—two factors that lend to its $475,000 price tag. Similar therapies are in the pipeline, but the cost and time it … |
